Loading…
← CockpitCompetitor Analysis › 2171.HK CARsgen Therapeutics Holdings Ltd.Open in the cockpit ↗

CARsgen Therapeutics Holdings Ltd.2171.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Pharmaceuticals: Major
Momentum laggard 17
Mkt cap
$751M
US dollars, full cap
Free float
57%
of shares outstanding
$/day
$2.33M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 11.2%
Hurdle
n/a
no reverse DCF
Next earnings
125 days
23 Mar 2027
Close · HKDHK$10.10
1D-3.4%
1W-9.5%
1M-16.2%
3M-32.2%
6M-44.5%
YTD-32.0%
1Y-38.5%
ATR %6.5%
52w lowhigh64.7% off high

What CARsgen Therapeutics does

Employees: 362

CARsgen Therapeutics at a glance

Size CARsgen Therapeutics (2171.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $751M, the 653rd largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$10.10 on 18 Nov 2026.

Performance Over six months the shares fell 44.5%, against -9.4% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 2nd lowest of 20 in its peer set.

Growth Revenue grew 68.1% over the last twelve months (peer median +2.8%); the operating margin is -170.5% (peer median 9.7%).

Valuation It trades at 28.6× enterprise value to sales against a peer median of 2.5× (most expensive of 19).

Next results Next results expected around 23 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 932171.HK 57
Six months, rebased to 100: CARsgen Therapeutics against the median of its 20 peers (local-currency closes).

CARsgen Therapeutics financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$152MHK$136MHK$42.7MHK$0HK$0
Revenue growth—+219%———
Gross profitHK$72.2MHK$54.7M-HK$66.2M-HK$96.6M-HK$94.8M
EBITDA-HK$228M-HK$223M-HK$577M-HK$780M-HK$854M
Net income-HK$101M-HK$106M-HK$865M-HK$826M-HK$1.04B
Free cash flow-HK$205M-HK$260M-HK$439M-HK$460M-HK$893M
Capital expenditureHK$10.7MHK$6.65MHK$21.2MHK$10.6MHK$161M
Total debtn/aHK$68.1MHK$177MHK$93.8MHK$134M

Quarterly statements and history in the cockpit →

CARsgen Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-25%0%+25%+50%0029070024246004793001LXRX2186002390600530BLISSGVS688799SGMT000411ARDX2171.HK6-month return →1-month return →
Up and to the right = strong over both horizons. CARsgen Therapeutics is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%0×10×20×30×0029070024246004793001LXRX2186002390688566600530BLISSGVSARDX603998057045342171.HKRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. CARsgen Therapeutics is the large dot.

CARsgen Therapeutics competitors and peer comparison

How CARsgen Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

CARsgen Therapeutics against its 20 peers (data as of 18 Nov 2026)
Measure2171.HKPeer medianRank in peer set
1-month return-16.2%-4.5%3rd lowest of 20
6-month return-44.5%-9.4%2nd lowest of 20
Distance from 52-week high-64.7%-33.7%lowest of 20
Revenue growth (TTM)+68.1%+2.8%highest of 20
Operating margin-170.5%9.7%lowest of 20
EV / Sales28.6×2.5×most expensive of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
CARsgen Therapeutics 2171.HKHong Kong$751M-45%+68%-170%28.6×n/an/a
Chongqing Pharscin Pharmaceutical 002907.SZChina$752M-7%+8%10%5.3×9.4%-1.4%
Guizhou Bailing Group Pharmaceutical 002424.SZChina$755M-20%-25%2%2.5×13.5%-0.2%
Zhuzhou Qianjin Pharmaceutical 600479.SSChina$746M-3%+4%11%1.4×-2.1%0.0%
Katakura Industries 3001.TJapan$765M+40%-2%15%2.4×0.3%+0.5%
Hunan Jiudian Pharmaceutical 300705.SZChina$738M-20%-5%13%1.8×-2.0%+26.1%
Lexicon Pharmaceuticals LXRXUnited States$766M-22%-46%-147%16.7×n/an/a
Luye Pharma 2186.HKHong Kong$736M-32%+3%18%1.1×-11.8%+1.9%
Guizhou Xinbang Pharmaceutical 002390.SZChina$771M-7%-13%4%0.9×-3.8%-0.8%
Jiangsu Jibeier Pharmaceutical 688566.SSChina$727M-9%+8%26%3.8×5.9%+11.3%
Shanghai Jiaoda Onlly 600530.SSChina$726M-25%-2%-2%16.1×42.7%-0.9%
Bliss GVS Pharma BLISSGVS.NSIndia$777M+141%+25%18%6.7×33.9%+10.1%
Sichuan Neautus Traditional Chinese 2206.HKHong Kong$779Mn/a+7%8%n/an/an/a
Hunan Warrant Pharmaceutical 688799.SSChina$725M-34%-3%9%3.9×n/an/a
Sagimet Biosciences SGMTUnited States$722M+52%n/an/an/an/an/a
Zhejiang Int'l 000411.SZChina$783M-21%+3%3%0.3×n/an/a
Ardelyx ARDXUnited States$784M-50%+18%-8%1.6×n/an/a
Jinghua Pharmaceutical 002349.SZChina$785M-8%+2%20%3.1×-2.5%+2.6%
Hunan Fangsheng Pharmaceutical 603998.SSChina$719M-1%+12%20%2.6×-4.8%+6.4%
China Traditional Chinese Medicine 0570.HKHong Kong$716M-31%-16%0%0.3×n/an/a
Mochida Pharmaceutical 4534.TJapan$714M-3%+16%10%0.8×n/an/a

Questions

Which companies are CARsgen Therapeutics's closest peers?
The cockpit's peer set: Chongqing Pharscin Pharmaceutical (002907.SZ), Guizhou Bailing Group Pharmaceutical (002424.SZ), Zhuzhou Qianjin Pharmaceutical (600479.SS), Katakura Industries (3001.T), Hunan Jiudian Pharmaceutical (300705.SZ), Lexicon Pharmaceuticals (LXRX), Luye Pharma (2186.HK), Guizhou Xinbang Pharmaceutical (002390.SZ).
Is CARsgen Therapeutics expensive compared with its peers?
On ev / sales it trades at 28.6× against a peer median of 2.5×, most expensive of 19 in its peer set.
How has CARsgen Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned -44.5% against -9.4% for the median peer; over one year -38.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.